培维索孟(Pegvisomant) - 药物靶点：GHR_在研适应症：肢端肥大症_专利_临床

概要

基本信息

药物类型

激素

别名

pegviosomant、Pegvisomant (genetical recombination) (JAN)、Pegvisomant (USAN/INN)

+ [7]

靶点

GHR

作用方式

拮抗剂

作用机制

GHR拮抗剂(生长激素受体拮抗剂)

治疗领域

神经系统疾病内分泌与代谢疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

肢端肥大症

非在研适应症

晚期恶性实体瘤乳腺癌结直肠癌+ [3]

原研机构

Sensus USA, Inc.

在研机构

Pharmacia & Upjohn LLCPfizer Europe MA EEIG

Pfizer Inc.

+ [1]

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

欧盟 (2002-11-12),

肢端肥大症

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (韩国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

Sequence Code 61626

来源: *****

关联

38

项与培维索孟相关的临床试验

NCT05470504

/ Recruiting临床2期IIT

Phase II Study of Growth Hormone Inhibition Using Pegvisomant In Severe Insulin Resistance

Background:
Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue. Many people with LDs become severely insulin resistant. Some people are insulin resistant because of a variant in the insulin receptor gene. Insulin resistance causes many health problems.
Objective:
To learn if blocking the effects of growth hormone in the body will help people with severe insulin resistance.
Eligibility:
Adults aged 18 to 65 years with either a known variant in the insulin receptor gene or with a diagnosis of partial LD.
Design:
Participants will have 2 hospital stays, about 1 month apart. Each stay will be 3 or 4 nights.
During each hospital stay, participants will have many tests. They will have a physical exam with blood tests. They will have all of their urine collected for a 24-hour period. They will have scans to measure their muscle, bone, and fat tissues. They will have tests to measure metabolism and insulin sensitivity. They may have an optional biopsy of fat tissue.
During the first hospital visit, participants will learn how to give themselves shots of a drug (pegvisomant) that blocks growth hormone. The drug is injected under the skin. Participants will continue to give themselves these shots once a day at home.
After the first hospital visit, participants will talk on the phone with members of the study team once each week. After 2 weeks they will have blood drawn for tests.
Participants will stop the shots after the second hospital visit.

开始日期2023-01-23

申办/合作机构

National Institute of Diabetes & Digestive & Kidney Diseases

NCT05131100

/ RecruitingN/A

Korean Post-marketing Surveillance for Somavert

Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)

开始日期2022-07-13

申办/合作机构

Pfizer Inc.

NCT04998500

/ Unknown statusN/AIIT

Growth Hormone as a Model for Reversible Activation of Adipose Tissue Fibrosis

Background: Adipose tissue fibrosis denotes excessive pathological accumulation of extracellular matrix (ECM) in adipose tissue and is a marker of dysfunction. Growth hormone (GH) activates adipose tissue lipolysis and stimulates collagen synthesis in lean tissues. Intriguingly, we have novel pilot data to suggest that GH excess (acromegaly) also induces reversible fibrosis in vivo and potently activates the expression of fibroblast activation protein alpha (FAPα).
Hypothesis: GH induces adipose tissue fibrosis by increased FAPα expression together with proliferation and fibrogenic differentiation of fibro-adipogenic progenitor (FAP) cells.
Aim: To unravel the mechanisms underlying GH-induced adipose tissue fibrosis with emphasis on FAPα expression and proliferation of FAP cells.
Subjects and methods: In a single blinded, randomized, double-dummy crossover design, 10 adult, moderately overweight individuals will be subjected to one week of GH and GH receptor blockade (Pegvisomant). We will use single-cell technologies, fluorescence-activated cell sorting (FACS), RNA sequencing, and cell culture studies on adipose tissue samples, combined with in vivo assessment of adipose tissue turnover and metabolism.
Perspectives: Understanding fibrosis formation in human models may identify new targets for treatment of obesity-associated disorders.

开始日期2021-08-01

申办/合作机构

University of Aarhus

[+1]

100 项与培维索孟相关的临床结果

登录后查看更多信息

100 项与培维索孟相关的转化医学

登录后查看更多信息

100 项与培维索孟相关的专利（医药）

登录后查看更多信息

545

项与培维索孟相关的文献（医药）

2025-11-01·Nature Reviews Endocrinology

Consensus on acromegaly therapeutic outcomes: an update

Review

作者: Buchfelder, Michael ; Luque, Raúl M ; Melmed, Shlomo ; Luger, Anton ; Petersenn, Stephan ; Colao, Annamaria ; Marazuela, Mónica ; van der Lely, Aart Jan ; Esposito, Daniela ; Frara, Stefano ; Mortini, Pietro ; Ioachimescu, Adriana G ; Giustina, Andrea ; Brue, Thierry ; Beckers, Albert ; Webb, Susan M ; Fleseriu, Maria ; Valassi, Elena ; Shimon, Ilan ; Kadioglu, Pinar ; Tsagarakis, Stylianos ; Ferone, Diego ; Biermasz, Nienke ; Katznelson, Laurence ; Salvatori, Roberto ; Chanson, Philippe ; Chiloiro, Sabrina ; Pirchio, Rosa ; Mercado, Moisés ; Losa, Marco ; Greenman, Yona ; Gurnell, Mark ; Zatelli, Maria Chiara ; Maffei, Pietro ; Bollerslev, Jens ; Kaiser, Ursula B ; Strasburger, Christian J ; Ho, Ken K Y ; Pereira, Alberto M ; Biller, Beverly M K ; Schilbach, Katharina ; Boguszewski, Cesar L ; Casanueva, Felipe F ; Gadelha, Monica R ; Clemmons, David R ; Geer, Eliza B ; Lamberts, Steven W J ; Samson, Susan L ; Neggers, Sebastian ; Puig-Domingo, Manel ; Karavitaki, Niki ; di Filippo, Luigi

The 15th Acromegaly Consensus Conference in September 2023 updated recommendations on therapeutic outcomes for acromegaly. Since the publication of medical management guidelines in 2018, new pharmacological agents and new treatment approaches have been developed. Fifty-two experts in the management of acromegaly reviewed the current literature and assessed changes in drug approvals, clinical practice standards and management. Current outcome goals were considered, with a focus on the effect of current and emerging somatostatin receptor ligands, the growth hormone receptor antagonist pegvisomant and the dopamine agonist cabergoline on biochemical control, clinical control, adenoma mass and surgical outcomes. Participants assessed factors that determine pharmacological choices, as well as the proposed use of each agent. Here, we present consensus recommendations highlighting how an evidence-based acromegaly management algorithm could be optimized in clinical practice.

2025-10-01·Endocrine Metabolic & Immune Disorders-Drug Targets

The Role of the GH Receptor Polymorphisms as a Prognostic Factor of Vertebral Fractures in Acromegalic Patients Resistant to First-generation SSAs and Treated with Pegvisomant or Pasireotide LAR

Article

作者: Giampietro, Antonella ; De Marinis, Laura ; Chiloiro, Sabrina ; Pontecorvi, Alfredo ; Infante, Amato ; Bianchi, Antonio ; Costanza, Flavia ; Angelini, Flavia

Background::

Acromegaly is associated with skeletal fragility and increased prevalence of vertebral fractures (VF). Two isoforms of GH receptor (GHR) have been described, which differ in the presence or absence of a transcript of exon 3 of the GHR gene. Both isoforms produce a functional receptor, but the exon 3-deleted isoforms (d3-GHR) have greater sensitivity to endogenous and recombinant GH than the full-length isoform (fl-GHR).

Objective::

We conducted a longitudinal, retrospective, observational, single-center study to investigate the role of GHR polymorphism as a prognostic factor of incidental VF (I-VF) in firstgeneration somatostatin analogs (fg-SSAs)-resistant acromegalic patients and treated with Pegvisomant or Pasireotide LAR.

Methods::

Seventy-two patients with active acromegaly were included: 28 patients carried the d3-GHR isoform, and 44 patients carried the fl-GHR isoform. Forty-six patients were treated with Pegvisomant in combination with fg-SSAs, and 26 were treated with Pasireotide LAR. At the last follow-up, 58 patients achieved biochemical control of acromegaly. Eighteen patients carried prevalent VF (P-VFs), while 14 patients experienced the occurrence of I-VFs.

Results::

From the group treated with Pegvisomant in combination with fg-SSAs, 32 patients carried the fl-GHR isoform, and 14 carried the d3-GHR isoform. From the group treated with Pasireotide LAR, 12 patients had the fl-GHR isoform, and 14 patients carried the d3-GHR isoform. I-VF occurred more frequently in patients with the fl-GHR isoform compared to d3-GHR (p =0.04); otherwise, I-VF occurred more frequently in patients with the d3-GHR isoform than fl-GHR (p =0.01).

Conclusion::

The GHR polymorphisms could improve the therapeutic approach in acromegaly, tailored to the individual patient, in the context of personalized medicine.

2025-08-01·PROTEIN SCIENCE

Growth hormone receptor antagonists, GHA2 and GHA3, with dual activity against the human and mouse receptor

Article

作者: Harms, Julia ; Wang, Yue ; Jamieson, Stephen M. F. ; Perry, Jo K. ; Langley, Ries J. ; Portlock, Theo

Abstract:

Aberrant human growth hormone (GH) expression has been increasingly linked to poor outcomes in certain cancers and reduced health span. GH receptor (GHR) signal transduction activates signaling pathways that promote cell proliferation and survival, contributing to tumor progression. Consequently, there has been growing interest in creating antagonists that target GH signaling for anticancer applications. Pegvisomant is the only clinically available GHR antagonist (GHA). It is a protein antagonist that consists of a mutated GH protein (B2036) conjugated to polyethylene glycol (PEG). While pegvisomant is a potent human GHR antagonist, it has lower efficacy in mice, necessitating the use of higher doses in preclinical models. Here, we describe two antagonists, GHA2 and GHA3, based on an earlier reported antagonist, B2024, that have improved efficacy in mice. Recombinant GHA2 and GHA3 were produced in E. coli and then conjugated to multiple 5 kDa amine‐reactive mPEG (GHA2‐PEG5K) or site‐specifically PEGylated with 40 kDa mPEG at amino acid site 144 (GHA3‐PEG40K). When compared with B2036, GHA2 and GHA3 had significantly improved in vitro activity against the mouse GHR in a Ba/F3 cell viability assay, and GHA2 more effectively reduced GH‐dependent signal transduction in the mouse melanoma cell line, B16‐F10. A single dose of 30 mg/kg of amine‐PEGylated GHA2‐PEG5K or site‐specific conjugate, GHA3‐PEG40K, reduced serum IGF‐1 in mice at 24 h by 40.7% and 45.8%, respectively. In contrast, amine‐PEGylated B2036‐PEG5K did not significantly reduce serum IGF‐I levels. In conclusion, we demonstrate here that GHA2‐PEG5K and GHA3‐PEG40K are more potent inhibitors than B2036‐PEG5K in mouse models.

4

项与培维索孟相关的新闻（医药）

2025-07-14

·PipelineReview

Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the presentation of preclinical data on MAR002, a novel growth hormone receptor (GHR) antagonist antibody for the treatment of acromegaly, at the 2025 Annual Meeting of the Endocrine Society (ENDO). The oral presentation, titled “Development of a Novel Growth Hormone Receptor Antagonist Antibody for the Treatment of Acromegaly,” highlights the significant potential of MAR002 to address critical unmet needs in patients suffering from this rare and highly morbid disease. Presentation highlights include: Marea Therapeutics has completed a GLP-toxicology study to assess MAR002’s safety. The preclinical pharmacology data strongly support advancing MAR002 into clinical development; a Phase 1 first-in-human study is expected to begin in the third quarter of 2025. Marea’s development strategy aims for rapid advancement into acromegaly patients after achieving proof of mechanism in healthy volunteers, with a clear path to approval guided by FDA guidance for IGF-1 normalization. “The preclinical data presented at ENDO 2025 underscore the potential of MAR002 to meaningfully transform the treatment landscape for acromegaly,” said Ethan Weiss, M.D., chief scientific officer of Marea Therapeutics. “With its strong potency, enhanced durability, and favorable developability profile, MAR002 is uniquely positioned to overcome the limitations of current therapies and offer a more effective, targeted approach for patients. We are excited to advance MAR002 into clinical development and bring forward a next generation and potential best-in-class GHR antagonist.” Marea Therapeutics believes MAR002 represents a significant opportunity to replace and expand the market for existing growth hormone receptor antagonists (GHRAs) and could also be used in combination with somatostatin receptor ligands (SRLs), offering a more effective and convenient treatment option for patients with acromegaly. About MAR002 MAR002 is a novel, potent and selective half-life-extended, allosteric, human monoclonal GHRA antibody being developed for the treatment of acromegaly. The PK and PD properties of MAR002 are predictable and typical of a half-life extended human antibody, showing a long duration of action compatible with infrequent subcutaneous dose administration in humans. These characteristics support its potential to offer an effective and convenient treatment for patients with acromegaly. About Acromegaly Acromegaly is an orphan disease characterized by the excess secretion of growth hormone (GH) from a benign pituitary adenoma. Acromegaly affects approximately 30,000 patients in the U.S. If left untreated, acromegaly is highly morbid, leading to significant comorbidities such as GH-induced insulin resistance and diabetes, and serious cardiovascular pathology. The median lifespan of patients can be shortened by 10 years without effective therapy, and incomplete IGF-1 normalization is associated with increased mortality. Despite its severity, acromegaly is often under or misdiagnosed, with an average time from symptom onset to diagnosis of approximately eight years. The current treatment paradigm for acromegaly often involves surgery, performed in over 90% of patients, which achieves remission in about 50% of cases, though this can degrade over time. Medical therapy is required for approximately 65% (around 20,000 in the U.S.) of patients during their disease journey, regardless of their surgical history. Current medical treatments include somatostatin receptor ligands (SRLs) and growth hormone receptor antagonists (GHRAs), such as pegvisomant. However, many patients do not achieve biochemical control with existing therapies. About Marea Therapeutics Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company’s lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for atherosclerotic cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X . SOURCE: Marea Therapeutics

临床2期孤儿药临床1期

2024-05-30

·蒲公英Ouryao

又有35个品规儿童药鼓励研发申报

转自：国家卫健委编辑：水晶5月30日，国家卫健委药物政策与基本药物制度司公示第五批鼓励研发申报儿童药品建议清单。公示清单共35个品规，这些品规是国内未注册上市且临床急需的儿童用药。35个第五批公示品规：阿尼芬净（注射剂）、柯拉特龙（乳膏剂）、头孢罗膦（注射剂）、艾伐卡托（颗粒剂）、阿托伐他汀混悬剂、达比加群酯（微丸）、索利那新（混悬剂）、托吡酯（口服溶液剂）、托法替布（口服溶液剂）、西替利嗪（注射剂）、伊伐雷定（口服溶液剂）、氨曲南（吸入溶液剂) 、甲苯磺酸托氟沙星（颗粒剂、片剂）、美替拉酮（胶囊剂）、谷卡匹酶（注射剂）、舒噻美（口服混悬液）、匹莫齐特（片剂）、培维索孟（注射液）、阿昔单抗（注射剂）、瑞斯利珠单抗（注射剂）、卡拉西珠单抗（注射剂）、艾哌依卡基（注射剂）、瑞利珠单抗（注射剂）。第四批24个品种：涉及30个品规、9种剂型，覆盖神经系统用药、消化道和新陈代谢用药、抗肿瘤药及免疫调节剂等治疗领域。<<详见24个品种！四部门联合印发（第四批）鼓励研发申报儿童药品清单>>前三批105种：2016年以来，国家卫生健康委会同有关部门，先后制定并发布了三批含105种药品的《鼓励研发申报儿童药品清单》。为进一步落实原国家卫生计生委等6部门《关于保障儿童用药的若干意见》要求，丰富儿童适用药品的品种、剂型和规格，满足儿科临床用药需求，2024年，国家卫生健康委、工业和信息化部和国家药监局继续紧密围绕我国儿童疾病谱以及相关企业研发生产能力，组织临床、药学、研发、注册等有关专家结合中国大陆境内尚未注册上市且临床急需的儿童用药现状，基于循证原则筛选论证，提出了《第五批鼓励研发申报儿童药品建议清单》。现予以公示，公示5个工作日。如有异议，请通过以下电话予以反映。电话：（010）68791740 附件：第五批鼓励研发申报儿童药品建议清单药物政策与基本药物制度司 2024年5月30日

上市批准

2024-03-19

·BioSpace

Crinetics Bags Second Phase III Win for Acromegaly, Heads for NDA Submission

Pictured: Blood sample for insulin-like growth factor-1 (IGF-1)/iStock, Jarun011 Crinetics Pharmaceuticals has secured another late-stage win as its oral, once-daily investigational drug paltusotine aced a second Phase III study for acromegaly, a rare hormonal disorder. The biotech’s stock shot up over 10% Tuesday morning following the announcement. In the late-stage trial, 56% of patients taking paltusotine achieved the primary endpoint for the insulin-like growth factor 1 (IGF-1) level compared to 5% on placebo. The treatment also helped reduce symptoms of the disease—a secondary endpoint of the study. No serious adverse events were reported. Acromegaly, sometimes referred to as gigantism, is a serious hormonal disorder caused by a benign tumor in the pituitary gland that secretes growth hormone. Over 25,000 patients in the U.S. suffer from the rare disease, which results in enlargement of face, hands and feet. Left untreated, it can cause type 2 diabetes, hypertension, heart disease and other serious complications. Surgical removal of the tumor is the preferred treatment but many patients are not candidates for surgery. Current pharmacological options include painful monthly injections or Pfizer’s subcutaneous daily injection of Somavert. The Phase III data are the second positive trial results for Crinetics in acromegaly. In September 2023, the biotech shared data for a study of paltusotine in patients who switched from their current injections to Crinetics’ pill. Among treated patients, 83% were able to maintain their IGF-1 levels within the upper limit of normal, compared to only 4% of those on placebo. With these data in hand, Crinetics plans to submit its New Drug Application to the FDA in the second half of this year, while prepping for a 2025 launch. Jefferies analysts believe the market opportunity could be around $300 million for the company. Crinetics is also testing the drug candidate in carcinoid syndrome, reporting positive Phase II topline results last week. Kate Goodwin is a freelance life science writer based in Des Moines, Iowa. She can be reached at kate.goodwin@biospace.com and on LinkedIn.

临床3期临床结果临床2期申请上市

100 项与培维索孟相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05394	培维索孟	H01AX01	DB00082

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肢端肥大症	欧盟	Pfizer Europe MA EEIG	2002-11-12
肢端肥大症	冰岛	Pfizer Europe MA EEIG	2002-11-12
肢端肥大症	列支敦士登	Pfizer Europe MA EEIG	2002-11-12
肢端肥大症	挪威	Pfizer Europe MA EEIG	2002-11-12

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床1期	美国	Pfizer Inc.	2009-11-01
晚期恶性实体瘤	临床1期	加拿大	Pfizer Inc.	2009-11-01
晚期恶性实体瘤	临床1期	芬兰	Pfizer Inc.	2009-11-01
晚期恶性实体瘤	临床1期	德国	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	美国	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	加拿大	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	芬兰	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	德国	Pfizer Inc.	2009-11-01
结直肠癌	临床1期	美国	Pfizer Inc.	2009-11-01
结直肠癌	临床1期	加拿大	Pfizer Inc.	2009-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01538966 (CTgov)	N/A	肢端肥大症	76	Octreotide LAR+Lanreotide+Pegvisomant (High Dose SRL + Weekly Pegvisomant)	膚襯選齋廠淵艱積憲蓋(繭鏇蓋製壓積鑰鏇網願) = 窪膚網製齋憲襯鹽觸糧鹹蓋蓋觸鏇衊醖淵糧糧 (襯壓壓範壓鹹窪簾襯廠, 1,645.49) 更多	-	2023-01-04
NCT01538966 (CTgov)	N/A	肢端肥大症	76	Octreotide LAR+Lanreotide+Pegvisomant (Low Dose SRL + Daily Pegvisomant)	膚襯選齋廠淵艱積憲蓋(繭鏇蓋製壓積鑰鏇網願) = 遞構鏇積蓋糧選醖願構鹹蓋蓋觸鏇衊醖淵糧糧 (襯壓壓範壓鹹窪簾襯廠, 11,158.49) 更多	-	2023-01-04
ENDO2020	N/A	肢端肥大症 blood glucose \| serum IGF-I levels \| hemoglobin A1c	72	Pegvisomant	憲蓋蓋醖蓋鬱築選構壓(鏇構製壓壓蓋鹽鑰簾築) = 鏇繭廠餘範糧獵襯顧繭鹹醖糧鑰繭獵築鑰齋觸 (淵簾範構醖餘廠範憲鑰 ) 更多	-	2020-05-08
ENDO2020	N/A	肢端肥大症 blood glucose \| serum IGF-I levels \| hemoglobin A1c	72	Pasireotide LAR	憲蓋蓋醖蓋鬱築選構壓(鏇構製壓壓蓋鹽鑰簾築) = 壓壓顧顧鏇網構醖願鏇鹹醖糧鑰繭獵築鑰齋觸 (淵簾範構醖餘廠範憲鑰 )	-	2020-05-08
SUN-LB079 (ENDO2019)	N/A	肢端肥大症	2,221	Pegvisomant	醖鏇餘繭齋網範築壓選(醖衊選夢積餘蓋積鬱艱) = 顧鑰築構鑰遞觸鏇願壓範廠鹽鏇襯顧遞製蓋衊 (憲壓淵網衊齋膚蓋構壓 ) 更多	-	2019-04-30
ACROSTUDY (ENDO2019)	N/A	肢端肥大症	110	Pegvisomant	觸構衊製網鹹網選繭觸(醖膚網窪構積顧鏇鏇艱) = 範廠淵鑰願鏇膚糧鬱鏇顧遞醖鑰廠壓繭願製構 (積衊膚遞窪廠鹹選鬱積, 5.4 ~ 6.1)	-	2019-04-30
NCT01261000 (CTgov)	N/A	肢端肥大症	8	Pegvisomant	鏇築糧鹽願構廠獵襯壓(齋顧淵齋艱襯鑰觸糧艱) = 願獵膚憲鹹齋範鬱壓憲夢糧鏇獵網製繭簾網鏇 (鹹製衊遞顧淵鏇艱選獵, 107.33) 更多	-	2017-08-22
NCT02023918 (PEGIR, CTgov)	临床2期	代谢综合征 \| 糖尿病前期	6	pegvisomant	選顧糧窪繭築膚鹹艱築(壓獵顧簾鏇鹹積獵鏇壓) = 獵窪鑰衊衊鹹憲鹽淵衊齋鑰衊餘鬱壓膚獵製構 (鬱淵淵鏇製遞獵築範範, 1.46) 更多	-	2017-03-13
NCT00976508 (CTgov)	临床1期	肉瘤 \| 肺癌 \| 晚期恶性实体瘤 ... 更多	24	Figitumumab+Pegvisomant (Figitumumab 20mg/kg + Pegvisomant 10 mg)	淵憲壓蓋獵遞憲築繭壓 = 壓憲鹹鑰顧廠艱糧餘遞餘壓網選鏇獵窪艱廠範 (衊鏇繭憲蓋糧顧憲蓋鏇, 鏇簾顧廠鑰簾鹹選範淵 ~ 鑰壓蓋衊遞壓繭網窪鹹) 更多	-	2013-12-13
NCT00976508 (CTgov)	临床1期	肉瘤 \| 肺癌 \| 晚期恶性实体瘤 ... 更多	24	Figitumumab+Pegvisomant (Figitumumab 20mg/kg + Pegvisomant 20 mg)	淵憲壓蓋獵遞憲築繭壓 = 廠襯積網選淵觸遞願糧餘壓網選鏇獵窪艱廠範 (衊鏇繭憲蓋糧顧憲蓋鏇, 廠鹽構醖顧餘壓醖淵艱 ~ 糧壓膚淵壓鏇網觸製範) 更多	-	2013-12-13
NCT00969644 (Pubmed \| Andrology)	N/A	-	8	GH treatment	艱鹽壓願簾選願糧遞醖(衊廠鬱製餘鹹壓觸網餘) = 衊醖糧鹽糧築範醖願獵顧繭衊簾淵獵觸築壓糧 (膚夢構網襯築鏇鏇鏇艱 ) 更多	-	2013-07-01
NCT01278342 (HOSCAR, CTgov)	临床4期	肢端肥大症	70	Sandostatin LAR (Sandostatin LAR High Dose Alone)	廠膚鏇鏇遞鏇蓋簾願鹽 = 繭襯淵齋壓糧壓簾膚醖願窪鹹廠窪夢鏇願選夢 (憲獵齋膚壓鏇夢鏇鑰夢, 觸築範積淵構範艱窪鹽 ~ 夢鹽糧製夢願鏇夢齋蓋) 更多	-	2011-02-17
NCT01278342 (HOSCAR, CTgov)	临床4期	肢端肥大症	70	Sandostatin LAR+pegvisomant (Sandostatin LAR High Dose + Pegvisomat)	廠膚鏇鏇遞鏇蓋簾願鹽 = 選遞鬱醖網夢範鏇艱齋願窪鹹廠窪夢鏇願選夢 (憲獵齋膚壓鏇夢鏇鑰夢, 鏇淵積醖醖獵鏇遞鬱願 ~ 膚襯顧膚壓鹹鹹憲製構) 更多	-	2011-02-17